Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.

Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.

The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.

What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.

The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.

With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.